Paclitaxel/ifosfamide or navelbine/ifosfamide chemotherapy for advanced non-small cell lung cancer: CALGB 9532

In order to explore non-cisplatin containing regimens for advanced non-smal l cell lung cancer, Cancer and Leukemia Group B conducted a randomized Phas e-II study of two novel combinations, paclitaxel/ifosfamide and vinorelbine /ifosfamide, Both regimens were active with a 38% response rate (95% CI: 24 %, 53%) and 31% (95% CI: 18%, 47%), respectively, Median survivals were 8.5 and 7.4 months. Toxicity, mostly neutropenia, was acceptable. These two co mbinations establish a 'proof of principle' that non-cisplatin containing r egimens also have activity in this setting. (C) 2000 Elsevier Science Irela nd Ltd. All rights reserved.